Últimas noticias sobre Core & Main (NYSE:CNM) Bolsa

CORE & MAIN INC-CLASS A

Core & Main

Core & Main Inc is a specialty distributor focusing on water, wastewater, storm drainage, and fire protection products and services. Catering to municipalities, private water companies, and contractors, it serves municipal, non-residential, and residential markets nationwide. Its diverse product line includes pipes, valves, fittings, storm drainage products, fire protection products, and meter products. Revenue is principally generated from pipes, valves, and fittings. The company operates across three construction sectors: municipal, non-residential, and residential, contributing to reliable infrastructure development nationwide.

Casey's General Store

Pre-Market Outlook

Trading Ideas

CASY

CVGW

UNFI

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: CNM, CVGW, SJM, CASY y UNFI.

5 acciones en el foco este martes: CNM, CVGW, SJM, CASY y UNFI

Core & Main, Inc.

Equities

News

Markets

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este martes: CNM, KBH, GME, DJT y WOR.

5 acciones en el foco este martes:CNM, KBH, GME, DJT y WOR

5 acciones en el foco este martes: CNM, KBH, GME, DJT y WOR

Core & Main Inc

Conmed Corp

CHINA MERCHANTS SECS ADR by China Merchants Securities Co.,Ltd

China Merchants Securities Asset Management Co.,Ltd

Canadian Metals Inc

CANADIAN METALS INC by Canadian Metals Inc.

CANOE MINING VENTURES by Canoe Mining Ventures Corp.

Canoe Mining Ventures Corp

Canamex Gold Corp

Compass Point analyst Ed Engel initiates coverage on Circle Internet Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRCL#NYSE">CRCL</a>) with a Neutral rating and announces Price Target of $205.

Price Target

Initiation

Analyst Ratings

CRCL

Compass Point Initiates Coverage On Circle Internet Group with Neutral Rating, Announces Price Target of $205

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">216.70</td>
<td align="right">2.30</td>
<td align="right">1.07</td>
<td>2.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">245.43</td>
<td align="right">2.55</td>
<td align="right">1.04</td>
<td>73.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.26</td>
<td align="right">0.44</td>
<td align="right">0.86</td>
<td>219.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">104.75</td>
<td align="right">0.86</td>
<td align="right">0.82</td>
<td>2.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">144.52</td>
<td align="right">0.66</td>
<td align="right">0.45</td>
<td>9.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">42.23</td>
<td align="right">0.17</td>
<td align="right">0.40</td>
<td>2.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">132.66</td>
<td align="right">0.50</td>
<td align="right">0.37</td>
<td>13.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">81.67</td>
<td align="right">0.27</td>
<td align="right">0.33</td>
<td>2.5K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.42</td>
<td align="right">0.18</td>
<td align="right">0.22</td>
<td>14.2K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">85.25</td>
<td align="right">-0.78</td>
<td align="right">-0.91</td>
<td>436.8K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
To read more about sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 24, 2025

Biotech

General

ENVB

Enveric Biosciences Announces Additional Data Indicating EB-003 Acts As An Agonist Of Serotonin Receptor 5-HT1B

Management

PSTG

Pure Storage Appoints Tarek Robbiati As CFO, Succeeding Kevan Krysler, Effective Immediately

Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, has agreed to sell approximately 3.2 million shares of its common stock (Common Stock) to a select group of accredited investors in a registered direct offering (the Offering), at a price per share of $4.67. The Offering is expected to close on June 25, 2025, subject to the satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately $15.0 million, before deducting offering-related expenses payable by the Company.
The investors in the Offering include existing healthcare-focused institutional investors, executive officers, and members of the Company's Board of Directors.

Offerings

CADL

Candel Therapeutics Announces $15M Registered Direct Offering Of 3.2M Shares At $4.67 Per Share

Deutsche Bank analyst Matthew Niknam maintains CommScope Holding Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COMM#NASDAQ">COMM</a>) with a Hold and raises the price target from $6 to $7.5.

COMM

Deutsche Bank Maintains Hold on CommScope Holding Co, Raises Price Target to $7.5

22nd Century Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XXII#NASDAQ">XXII</a>), the only tobacco products company that is leading the fight against nicotine by offering smokers a choice about their nicotine consumption, today announced major updates to its Pinnacle product manufacturing and marketing agreement with its top-5 c-store chain customer, including the launch of four new Pinnacle SKUs, including two in the low nicotine product category. The agreement includes a merchandising agreement to potentially expand the availability of Pinnacle products to include other retail and c-store chains.
The new agreement includes two partner VLN products, Pinnacle VLN&#xAE; Gold cigarettes and Pinnacle Menthol VLN&#xAE; cigarettes which will be sold at approximately 1,700 stores across 27 states. Sales to customers are expected to begin in late summer and early fall of 2025, with stocking orders in advance, as state approvals are secured.

XXII

22nd Century Announces Updates To Pinnacle Product Manufacturing And Marketing Agreement With Top-5 C-Store Chain Customer; Launches Pinnacle VLN And Moist Snuff Products In More Than 1,700 Stores Across 27 States

<a href="https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm" title="https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm">https://www.sec.gov/Archives/edgar/data/87347/000119312525145388/d81921dex99.htm</a>

Guidance

Schlumberger N.V. Says Looking Broadly Across Energy Markets, There Has Been A Lot Of Uncertainty This Quarter; Commitment To Returning A Minimum Of $4B To Shareholders In 2025 Is Unchanged

Cantor Fitzgerald analyst Matthew Prisco maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Overweight and raises the price target from $90 to $105.

Cantor Fitzgerald Maintains Overweight on Teradyne, Raises Price Target to $105

Homeowners have on average, $181,000 in equity. This new product helps them access it before transitioning to a new home
DETROIT, June 24, 2025 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455287-1&amp;h=3636688888&amp;u=https%3A%2F%2Frocket.com%2Fmortgage%2F&amp;a=Rocket+Mortgage">Rocket Mortgage</a>, the nation's largest mortgage lender and a part of <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4455287-1&amp;h=1515700121&amp;u=https%3A%2F%2Fwww.rocketcompanies.com%2F&amp;a=Rocket+Companies">Rocket Companies</a>&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>), today announced the launch of bridge loans – a strategic solution designed to help buyers wrestle back control in today's competitive housing market. This new product allows current homeowners to use equity to compete shoulder-to-shoulder with cash buyers – allowing them to purchase their next primary residence before selling their current one. This provides both financial flexibility and eliminates the uncertainty and reluctance of home sellers that often comes with so-called 'contingent' offers.
With high home prices and tight housing inventory, many buyers struggle to compete without first selling – leading to delays and missed opportunities. Yet the average homeowner has $181,000 in untapped equity, a powerful resource to make a strong offer.¹ &nbsp;Rocket Mortgage's bridge loan unlocks that equity upfront, providing funds for a down payment or closing costs in the interim.

Rocket Mortgage Launches Bridge Loans To Help Homeowners Access Equity And Compete With Cash Buyers

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Goldman Sachs lowered Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) price target from $48 to $46. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. Advance Auto Parts shares closed at $51.93 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/AAP/analyst-ratings">view this stock</a>.</li>
<li>Guggenheim increased the price target for Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) from $50 to $68. Guggenheim analyst Seamus Fernandez maintained a Buy rating. Cidara Therapeutics shares closed at $44.95 on Monday. <a href="https://www.benzinga.com/quote/CDTX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Needham raised CorMedix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) price target from $15 to $20. Needham analyst Serge Belanger maintained a Buy rating. CorMedix shares closed at $16.56 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/CRMD/analyst-ratings">view this stock</a>.</li>
<li>HC Wainwright &amp; Co. boosted the price target for Lyell Immunopharma Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) from $1 to $10. HC Wainwright &amp; Co. analyst Mitchell Kapoor maintained a Neutral rating. Lyell Immunopharma shares closed at $8.99 on Monday. <a href="https://www.benzinga.com/quote/LYEL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs slashed the price target for RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) from $199 to $179. Goldman Sachs analyst Kate McShane downgraded the stock from Neutral to Sell. RH shares closed at $186.22 on Monday. <a href="https://www.benzinga.com/quote/RH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities cut DICK&#8217;S Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) price target from $250 to $240. B of A Securities analyst Robert Ohmes maintained a Buy rating. DICK&#8217;S Sporting shares settled at $175.79 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities raised MACOM Technology Solutions Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) price target from $250 to $270. B of A Securities analyst Vivek Arya maintained a Buy rating. MACOM Technology Solutions shares closed at $138.65 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc increased Westinghouse Air Brake Technologies Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAB#NYSE">WAB</a>) price target from $220 to $240. Keybanc analyst Steve Barger maintained an Overweight rating. Westinghouse Air Brake Technologies shares closed at $202.19 on Monday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald raised the price target for Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) from $200 to $220. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Applied Materials shares settled at $171.96 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cantor Fitzgerald increased Lam Research Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRCX#NASDAQ">LRCX</a>) price target from $90 to $115. Cantor Fitzgerald analyst Matthew Prisco maintained an Overweight rating. Lam Research shares closed at $91.61 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying AAP stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="554" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png" alt="" class="wp-image-959828" style="width:540px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-1024x554.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/24084704/image-361.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/46067537/blackberry-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-analysts">BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>
Photo via Shutterstock

AMAT

CDTX

CRMD

CTVA

LRCX

LYEL

MTSI

Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday

Cantor Fitzgerald analyst Matthew Prisco maintains Onto Innovation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONTO#NYSE">ONTO</a>) with a Neutral and lowers the price target from $110 to $90.

ONTO

Cantor Fitzgerald Maintains Neutral on Onto Innovation, Lowers Price Target to $90

Data from longest and largest hemophilia gene therapy study demonstrates sustained factor VIII expression and bleed control, with 81.3% of individuals remaining off prophylaxis
No new safety signals observed
SAN RAFAEL, Calif., June 24, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) today announced new data underscoring the long-term efficacy and safety of ROCTAVIAN&#xAE;&nbsp;(valoctocogene roxaparvovec-rvox) were presented at the 33rd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington, D.C., June 21-25, 2025.
The Phase 3 GENEr8-1 trial demonstrated that durable bleed control and sustained factor VIII (FVIII) expression were maintained five years after treatment with ROCTAVIAN. FVIII activity remained consistent with previously reported results, and no new safety signals were observed. Across the entire trial, no participants developed FVIII inhibitors or experienced thromboembolic events, and there were no treatment-related malignancies across the five years of the study.

BMRN

BioMarin Pharma Presents New Data Underscoring Long-Term Efficacy And Safety Of ROCTAVIAN At Congress Of ISTH

Contracts

ASNS

Actelis Receives Initial Order From A Telecommunications Carrier To Deploy Its GigaLine Solutions

GSK Announces FDA Approval Of Benlysta Autoinjector For children With Active Lupus Nephritis

PPSI

Pioneer Power Solutions Bags ~$10M Award From U.S. Charging-As-A-Service Company To Accelerate e-Boost Deployment

Cantor Fitzgerald analyst Matthew Prisco maintains Nova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVMI#NASDAQ">NVMI</a>) with a Overweight and raises the price target from $250 to $300.

NVMI

Cantor Fitzgerald Maintains Overweight on Nova, Raises Price Target to $300

Company research targets topical application for treatment of skin cancers
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bioaffinitytech.com&amp;esheet=54281272&amp;newsitemid=20250624870760&amp;lan=en-US&amp;anchor=bioAffinity+Technologies%2C+Inc.&amp;index=1&amp;md5=a85c3afa960a05417f2274483ca882b6">bioAffinity Technologies, Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>, BIAFW)), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company's novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane.
The newly allowed Chinese patent – titled "Compositions and Methods for Treating Cancer" – adds important global protection for bioAffinity's innovative RNA-based therapeutic strategy and covers siRNAs and their use in cancer treatment, which is also protected by the Company's new U.S. Patent No. 12,305,171.
The invention uses small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro research demonstrates this siRNA-driven double knockdown effectively targets cancer cells from multiple tumor types, including lung, breast, prostate, brain, and skin, without harming normal cells, suggesting a universal mechanism of action.
bioAffinity is exploring the application of this technology as a topical treatment specifically designed for cutaneous malignancies and neoplasms of the skin. This development aligns closely with the Company's broader strategy of addressing cancer through both early-stage diagnostics, exemplified by CyPath&#xAE; Lung, and innovative therapeutic approaches.
bioAffinity continues to advance its high-growth core diagnostic platform, CyPath&#xAE; Lung, an accurate, noninvasive test for early-stage lung cancer detection, while simultaneously leveraging its scientific expertise toward novel therapeutic solutions that address critical unmet medical needs in oncology.

BIAF

CNIPA Issues Notification Of Patent Grant For bioAffinity Technologies' Composition And Method For Selectively Killing Cancer By Targeting CD320 And LRP2 Receptors On Cell Membrane

CAPR

Capricor Therapeutics Provides Update On Deramiocel BLA, Says FDA Has Indicated An Advisory Committee Meeting Is Not Required At This Time

Cantor Fitzgerald analyst Matthew Prisco maintains MKS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKSI#NASDAQ">MKSI</a>) with a Overweight and raises the price target from $110 to $120.

MKSI

Cantor Fitzgerald Maintains Overweight on MKS, Raises Price Target to $120

Press Releases

Core & Main Completes Acquisition of ARGCO Northeast LLC

Core & Main to Announce Fiscal 2024 Third Quarter Results

Core & Main Announces Record Fiscal 2024 Third Quarter Results

Immokalee Water & Sewer District Modernizes with Xylem Digital Solutions

Core & Main to Announce Fiscal 2024 Fourth Quarter and Full-Year Results

Core & Main Announces Leadership Transition

Core & Main Announces Fiscal 2024 Fourth Quarter and Full-Year Results

Core & Main to Announce Fiscal 2025 First Quarter Results

Core & Main Named to Fortune 500 for First Time

Core & Main Announces Record Fiscal 2025 First Quarter Results

AerCap Holdings

Applied Industrial Technologies, Inc. Common Stock

Applied Industrial Techs

Air Lease Corporation Class A Common Stock

Air Lease

Boise Cascade

Dnow

Distribution Solutions Group, Inc. - Common Stock

Distribution Solns Gr

DXP Enterprises

Fastenal

Ferguson Enterprises

FTAI Aviation

GATX

W.W. Grainger

Herc Holdings

McGrath RentCorp

MRC Global

MSC Industrial Direct Company, Inc. Common Stock

MSC Industrial Direct Co

Rush Enterprises, Inc. - Class A Common Stock

Rush Enterprises

Rush Enterprises, Inc. - Class B Common Stock

SiteOne Landscape Supply, Inc. Common Stock

SiteOne Landscape Supply

United Rentals

WESCO Intl

Watsco

Xometry

Citigroup

RBC Capital

Loop Capital

Wells Fargo

JP Morgan

Comments

Core & Main

Noticias

Últimas noticias sobre Core & Main (NYSE:CNM) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL